

Leon W M M Terstappen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/451836/publications.pdf>

Version: 2024-02-01

258
papers

27,834
citations

14655

66
h-index

5539

163
g-index

262
all docs

262
docs citations

262
times ranked

17451
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 781-791.	27.0	4,124
2	Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases. <i>Clinical Cancer Research</i> , 2004, 10, 6897-6904.	7.0	2,261
3	Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6302-6309.	7.0	1,975
4	Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 3213-3221.	1.6	1,642
5	Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 1420-1430.	1.6	1,012
6	Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival. <i>Clinical Cancer Research</i> , 2006, 12, 4218-4224.	7.0	937
7	Circulating Tumor Cells in Patients with Breast Cancer Dormancy. <i>Clinical Cancer Research</i> , 2004, 10, 8152-8162.	7.0	846
8	Circulating Tumor Cells versus Imagingâ€”Predicting Overall Survival in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6403-6409.	7.0	728
9	Detection and characterization of carcinoma cells in the blood. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 4589-4594.	7.1	636
10	Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. <i>Journal of Oncology</i> , 2010, 2010, 1-8.	1.3	610
11	Characterization of <i>ERG</i> , <i>AR</i> and <i>PTEN</i> Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 2912-2918.	0.9	518
12	<i>HER-2</i> gene amplification can be acquired as breast cancer progresses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9393-9398.	7.1	498
13	Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2009, 20, 1223-1229.	1.2	449
14	Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate. <i>Journal of Clinical Oncology</i> , 2010, 28, 1489-1495.	1.6	370
15	Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 2023-2029.	7.0	329
16	Global Gene Expression Profiling of Circulating Tumor Cells. <i>Cancer Research</i> , 2005, 65, 4993-4997.	0.9	328
17	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2583-2593.	7.0	289
18	Challenges in circulating tumor cell detection by the CellSearch system. <i>Molecular Oncology</i> , 2016, 10, 395-407.	4.6	231

#	ARTICLE	IF	CITATIONS
19	The detection of EpCAM+ and EpCAM ^{hi} circulating tumor cells. <i>Scientific Reports</i> , 2015, 5, 12270.	3.3	223
20	Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 3938-3942.	7.1	218
21	Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. <i>Annals of Oncology</i> , 2009, 20, 27-33.	1.2	216
22	Circulating tumor cells predict survival in patients with metastatic prostate cancer. <i>Urology</i> , 2005, 65, 713-718.	1.0	211
23	Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. <i>Annals of Oncology</i> , 2012, 23, 2937-2942.	1.2	191
24	Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor. <i>Clinical Cancer Research</i> , 2007, 13, 3611-3616.	7.0	185
25	Statistical considerations for enumeration of circulating tumor cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2007, 71A, 154-162.	1.5	183
26	Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. <i>Annals of Oncology</i> , 2010, 21, 1006-1012.	1.2	183
27	All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2010, 21, 1851-1857.	1.2	179
28	Isolation and Characterization of Circulating Tumor Cells in Patients with Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2006, 6, 125-132.	2.3	169
29	Differential surface expression of cell adhesion molecules during granulocyte maturation. <i>Journal of Leukocyte Biology</i> , 1993, 54, 47-55.	3.3	164
30	Challenges in the Enumeration and Phenotyping of CTC. <i>Clinical Cancer Research</i> , 2012, 18, 5711-5718.	7.0	164
31	Formation of haematopoietic microenvironment and haematopoietic stem cells from single human bone marrow stem cells. <i>Nature</i> , 1992, 360, 745-749.	27.8	161
32	Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. <i>Breast Cancer Research</i> , 2012, 14, R133.	5.0	159
33	Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. <i>Urology</i> , 2001, 58, 386-392.	1.0	152
34	Filter Characteristics Influencing Circulating Tumor Cell Enrichment from Whole Blood. <i>PLoS ONE</i> , 2013, 8, e61770.	2.5	152
35	uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17361-17365.	7.1	149
36	Quality of extracellular vesicle images by transmission electron microscopy is operator and protocol dependent. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1555419.	12.2	140

#	ARTICLE	IF	CITATIONS
37	Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. <i>International Journal of Oncology</i> , 2005, 27, 49-57.	3.3	136
38	Apoptosis of circulating tumor cells in prostate cancer patients. <i>Cytometry</i> , 2004, 62A, 46-53.	1.8	131
39	Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. <i>International Journal of Oncology</i> , 2005, 27, 49.	3.3	126
40	Optimization of ferrofluids and protocols for the enrichment of breast tumor cells in blood. <i>Journal of Magnetism and Magnetic Materials</i> , 2001, 225, 301-307.	2.3	121
41	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. <i>European Urology</i> , 2016, 70, 985-992.	1.9	119
42	Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. <i>Cytometry Part B - Clinical Cytometry</i> , 2005, 68B, 25-30.	1.5	113
43	Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2007, 71A, 105-113.	1.5	113
44	Optical tracking and detection of immunomagnetically selected and aligned cells. <i>Nature Biotechnology</i> , 1999, 17, 1210-1213.	17.5	112
45	Characterization of circulating tumor cells by fluorescence in situ hybridization. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2009, 75A, 520-527.	1.5	107
46	Light-scattering polarization measurements as a new parameter in flow cytometry. <i>Cytometry</i> , 1987, 8, 539-544.	1.8	104
47	Discriminating between damaged and intact cells in fixed flow cytometric samples. <i>Cytometry</i> , 1988, 9, 477-484.	1.8	98
48	Quantitative Comparison of Myeloid Antigens on Five Lineages of Mature Peripheral Blood Cells. <i>Journal of Leukocyte Biology</i> , 1990, 48, 138-148.	3.3	98
49	Donor-Derived Long-Term Multilineage Hematopoiesis in a Liver-Transplant Recipient. <i>New England Journal of Medicine</i> , 1993, 328, 762-765.	27.0	97
50	Global Gene Expression Profiling of Circulating Endothelial Cells in Patients with Metastatic Carcinomas. <i>Cancer Research</i> , 2006, 66, 2918-2922.	0.9	89
51	Challenges for CTC-based liquid biopsies: low CTC frequency and diagnostic leukapheresis as a potential solution. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 147-164.	3.1	89
52	Self-seeding microwell chip for the isolation and characterization of single cells. <i>Lab on A Chip</i> , 2015, 15, 3039-3046.	6.0	88
53	Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. <i>Clinical Cancer Research</i> , 2018, 24, 5635-5644.	7.0	88
54	Importance of circulating tumor cells in newly diagnosed colorectal cancer. <i>International Journal of Oncology</i> , 2015, 46, 1361-1368.	3.3	87

#	ARTICLE	IF	CITATIONS
55	Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. <i>International Journal of Oncology</i> , 2002, 21, 1111-7.	3.3	85
56	Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer. <i>Molecular Oncology</i> , 2013, 7, 680-692.	4.6	82
57	Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. <i>PLoS ONE</i> , 2013, 8, e67148.	2.5	82
58	Label-Free Prostate Cancer Detection by Characterization of Extracellular Vesicles Using Raman Spectroscopy. <i>Analytical Chemistry</i> , 2018, 90, 11290-11296.	6.5	82
59	Filtration Parameters Influencing Circulating Tumor Cell Enrichment from Whole Blood. <i>PLoS ONE</i> , 2013, 8, e61774.	2.5	80
60	Improving the CellSearch® system. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1291-1305.	3.1	80
61	Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS. <i>Genome Medicine</i> , 2013, 5, 106.	8.2	79
62	Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis. <i>Cancers</i> , 2013, 5, 1619-1642.	3.7	76
63	Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. , 2019, 7, 173.		76
64	Five-dimensional flow cytometry as a new approach for blood and bone marrow differentials. <i>Cytometry</i> , 1988, 9, 548-556.	1.8	71
65	Multigene Reverse Transcription-PCR Profiling of Circulating Tumor Cells in Hormone-Refractory Prostate Cancer. <i>Clinical Chemistry</i> , 2004, 50, 826-835.	3.2	68
66	Physiological stress induces the metastasis marker AGR2 in breast cancer cells. <i>Molecular and Cellular Biochemistry</i> , 2007, 306, 255-260.	3.1	68
67	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). <i>International Journal of Cancer</i> , 2018, 143, 2584-2591.	5.1	68
68	EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 117, 60-68.	2.8	68
69	Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. <i>Annals of Oncology</i> , 2018, 29, 1554-1560.	1.2	65
70	Detection of cancer before distant metastasis. <i>BMC Cancer</i> , 2013, 13, 283.	2.6	64
71	Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1397-1403.	1.1	62
72	Circulating melanoma cells and survival in metastatic melanoma. <i>International Journal of Oncology</i> , 2011, 38, 755-60.	3.3	62

#	ARTICLE	IF	CITATIONS
73	Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model. <i>Nature Communications</i> , 2020, 11, 1884.	12.8	62
74	A rapid sample preparation technique for flow cytometric analysis of immunofluorescence allowing absolute enumeration of cell subpopulations. <i>Journal of Immunological Methods</i> , 1989, 123, 103-112.	1.4	59
75	Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. <i>Annals of Oncology</i> , 2013, 24, 1231-1238.	1.2	59
76	Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. <i>British Journal of Cancer</i> , 2015, 112, 1166-1174.	6.4	59
77	Analysis of cell surface antigens by Surface Plasmon Resonance imaging. <i>Biosensors and Bioelectronics</i> , 2014, 52, 36-43.	10.1	58
78	Increased light scattering resolution facilitates multidimensional flow cytometric analysis. <i>Cytometry</i> , 1990, 11, 506-512.	1.8	56
79	Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation. <i>Journal of Leukocyte Biology</i> , 1992, 52, 652-660.	3.3	54
80	Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. <i>Oncotarget</i> , 2018, 9, 19283-19293.	1.8	54
81	Impaired growth and elevated Fas receptor expression in PIGA+ stem cells in primary paroxysmal nocturnal hemoglobinuria. <i>Journal of Clinical Investigation</i> , 2000, 106, 689-696.	8.2	53
82	Detection of Circulating Tumor Cells. <i>Scientifica</i> , 2014, 2014, 1-11.	1.7	52
83	Circulating tumor cells before and during follow-up after breast cancer surgery. <i>International Journal of Oncology</i> , 2015, 46, 407-413.	3.3	52
84	Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival. <i>British Journal of Cancer</i> , 2020, 122, 801-811.	6.4	52
85	Magnetic field design for selecting and aligning immunomagnetic labeled cells. <i>Cytometry</i> , 2002, 47, 163-172.	1.8	51
86	Label-free imaging and identification of typical cells of acute myeloid leukaemia and myelodysplastic syndrome by Raman microspectroscopy. <i>Analyst</i> , The, 2015, 140, 1054-1064.	3.5	49
87	Single laser three color immunofluorescence staining procedures based on energy transfer between phycoerythrin and cyanine 5. <i>Cytometry</i> , 1991, 12, 723-730.	1.8	48
88	Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. <i>European Journal of Cancer</i> , 2010, 46, 2027-2035.	2.8	48
89	Immuno-capture of extracellular vesicles for individual multi-modal characterization using AFM, SEM and Raman spectroscopy. <i>Lab on A Chip</i> , 2019, 19, 2526-2536.	6.0	48
90	Deep learning of circulating tumour cells. <i>Nature Machine Intelligence</i> , 2020, 2, 124-133.	16.0	48

#	ARTICLE	IF	CITATIONS
91	Four-Parameter white blood cell differential counting based on light scattering measurements. <i>Cytometry</i> , 1988, 9, 39-43.	1.8	47
92	Coordinate expression of $\beta 1$ and $\beta 2$ integrin "activation" epitopes during T cell responses in secondary lymphoid tissue. <i>European Journal of Immunology</i> , 1993, 23, 2751-2757.	2.9	46
93	Single tube liquid biopsy for advanced non-small cell lung cancer. <i>International Journal of Cancer</i> , 2019, 144, 3127-3137.	5.1	45
94	Changes in the growth properties of CD34+, CD38- bone marrow progenitors during human fetal development. <i>Blood</i> , 1995, 86, 710-718.	1.4	44
95	Interpretation of Changes in Circulating Tumor Cell Counts. <i>Translational Oncology</i> , 2012, 5, 486-IN4.	3.7	43
96	International study on inter-reader variability for circulating tumor cells in breast cancer. <i>Breast Cancer Research</i> , 2014, 16, R43.	5.0	43
97	Detection and Characterization of Circulating Tumor Cells by the CellSearch Approach. <i>Methods in Molecular Biology</i> , 2015, 1347, 263-278.	0.9	43
98	Defective and normal haematopoietic stem cells in paroxysmal nocturnal haemoglobinuria. <i>British Journal of Haematology</i> , 1993, 84, 504-514.	2.5	42
99	Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival. <i>PLoS ONE</i> , 2011, 6, e27419.	2.5	42
100	Regulated Expression of the Eph-Related Receptor Tyrosine Kinase Hek11 in Early Human B Lymphopoiesis. <i>Blood</i> , 1997, 90, 3613-3622.	1.4	41
101	A comparison of breast cancer tumor cells with varying expression of the Her2/neu receptor by Raman microspectroscopic imaging. <i>Analyst, The</i> , 2010, 135, 3220.	3.5	39
102	Detecting Blood-Based Biomarkers in Metastatic Breast Cancer: A Systematic Review of Their Current Status and Clinical Utility. <i>International Journal of Molecular Sciences</i> , 2017, 18, 363.	4.1	39
103	Expression of Cell Surface Markers during Differentiation of CD34+, CD38 ^{hi} /lo Fetal and Adult Bone Marrow Cells. <i>ImmunoMethods</i> , 1994, 5, 179-188.	0.8	38
104	Cancer Stem Cells, Epithelial to Mesenchymal Markers, and Circulating Tumor Cells in Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 535-542.	2.6	38
105	Physical discrimination between human T-lymphocyte subpopulations by means of light scattering, revealing two populations of T8-positive cells. <i>Cytometry</i> , 1986, 7, 178-183.	1.8	37
106	Label-free identification and chemical characterisation of single extracellular vesicles and lipoproteins by synchronous Rayleigh and Raman scattering. <i>Journal of Extracellular Vesicles</i> , 2020, 9, 1730134.	12.2	37
107	Reconstructing single-cell karyotype alterations in colorectal cancer identifies punctuated and gradual diversification patterns. <i>Nature Genetics</i> , 2021, 53, 1187-1195.	21.4	37
108	The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab. <i>Annals of Oncology</i> , 2010, 21, 2447-2448.	1.2	34

#	ARTICLE	IF	CITATIONS
109	Microfluidic device for DNA amplification of single cancer cells isolated from whole blood by self-seeding microwells. <i>Lab on A Chip</i> , 2015, 15, 4331-4337.	6.0	34
110	How to Agree on a CTC: Evaluating the Consensus in Circulating Tumor Cell Scoring. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 1202-1206.	1.5	34
111	Classification of Cells in CTC-Enriched Samples by Advanced Image Analysis. <i>Cancers</i> , 2018, 10, 377.	3.7	34
112	Analysis of Released Circulating Tumor Cells During Surgery for Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1656-1666.	7.0	33
113	Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>JCO Precision Oncology</i> , 2021, 5, 1540-1553.	3.0	33
114	CellTracks TDI: An image cytometer for cell characterization. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2011, 79A, 203-213.	1.5	31
115	Automated identification of circulating tumor cells by image cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 138-148.	1.5	31
116	<i>CCR</i> 20th Anniversary Commentary: Paving the Way for Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2015, 21, 2883-2885.	7.0	31
117	Surface Plasmon Resonance is an Analytically Sensitive Method for Antigen Profiling of Extracellular Vesicles. <i>Clinical Chemistry</i> , 2017, 63, 1633-1641.	3.2	31
118	Health economic impact of liquid biopsies in cancer management. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 593-599.	1.4	31
119	Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapy. <i>Translational Lung Cancer Research</i> , 2019, 8, 854-861.	2.8	31
120	Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch® and ISET. <i>Cancers</i> , 2020, 12, 896.	3.7	31
121	Cell analysis system based on immunomagnetic cell selection and alignment followed by immunofluorescent analysis using compact disk technologies. <i>Cytometry</i> , 2001, 43, 31-37.	1.8	30
122	Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage. <i>Thrombosis and Haemostasis</i> , 2008, 100, 642-647.	3.4	30
123	Capture of Tumor Cells on Anti-EpCAM-Functionalized Poly(acrylic acid)-Coated Surfaces. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 14349-14356.	8.0	30
124	Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles. <i>Cancers</i> , 2018, 10, 416.	3.7	30
125	Automated Enumeration of CD34+ Cells in Peripheral Blood and Bone Marrow. <i>Stem Cells and Development</i> , 1994, 3, 3-13.	1.0	28
126	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 151-159.	5.4	28

#	ARTICLE	IF	CITATIONS
127	Quantifying HER-2 expression on circulating tumor cells by ACCEPT. PLoS ONE, 2017, 12, e0186562.	2.5	28
128	A single platform image cytometer for resource-poor settings to monitor disease progression in HIV infection. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2007, 71A, 132-142.	1.5	27
129	On-chip sample preparation by controlled release of antibodies for simple CD4 counting. Lab on A Chip, 2012, 12, 167-173.	6.0	27
130	Quantification of antibody production of individual hybridoma cells by surface plasmon resonance imaging. Analytical Biochemistry, 2015, 485, 112-118.	2.4	27
131	Multiscale Segmentation via Bregman Distances and Nonlinear Spectral Analysis. SIAM Journal on Imaging Sciences, 2017, 10, 111-146.	2.2	27
132	DNA Detection by Flow Cytometry using PNA-Modified Metal-Organic Framework Particles. Chemistry - A European Journal, 2017, 23, 4180-4186.	3.3	26
133	Proficiency Testing to Assess Technical Performance for CTC-Processing and Detection Methods in CANCER-ID. Clinical Chemistry, 2021, 67, 631-641.	3.2	25
134	Label-free cell profiling. Analytical Biochemistry, 2013, 439, 4-6.	2.4	24
135	Magnetic Particles for CTC Enrichment. Cancers, 2020, 12, 3525.	3.7	24
136	Discrimination of human cytotoxic lymphocytes from regulatory and B-lymphocytes by orthogonal light scattering. Journal of Immunological Methods, 1986, 95, 211-216.	1.4	23
137	Programmable v-type valve for cell and particle manipulation in microfluidic devices. Lab on A Chip, 2016, 16, 305-311.	6.0	23
138	Isolation of single cells for protein therapeutics using microwell selection and Surface Plasmon Resonance imaging. Analytical Biochemistry, 2017, 531, 45-47.	2.4	22
139	Platelet removal by single-step centrifugation. Platelets, 2021, 32, 440-443.	2.3	22
140	Flowcytometry - Principles and Feasibility in Transfusion Medicine. Enumeration of Epithelial Derived Tumor Cells in Peripheral Blood. Vox Sanguinis, 1998, 74, 269-274.	1.5	21
141	Imaging technique implemented in CellTracks system. Cytometry, 2002, 47, 248-255.	1.8	21
142	Synchronized Rayleigh and Raman scattering for the characterization of single optically trapped extracellular vesicles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102109.	3.3	21
143	Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients. Molecular Oncology, 2021, 15, 116-125.	4.6	21
144	CD38 in Advanced Prostate Cancers. European Urology, 2021, 79, 736-746.	1.9	21

#	ARTICLE	IF	CITATIONS
145	Parallel Single Cancer Cell Whole Genome Amplification Using Button-Valve Assisted Mixing in Nanoliter Chambers. PLoS ONE, 2014, 9, e107958.	2.5	21
146	StarDist Image Segmentation Improves Circulating Tumor Cell Detection. Cancers, 2022, 14, 2916.	3.7	21
147	Cancer-ID: Toward Identification of Cancer by Tumor-Derived Extracellular Vesicles in Blood. Frontiers in Oncology, 2020, 10, 608.	2.8	20
148	Presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection. Biosensors and Bioelectronics, 2021, 183, 113165.	10.1	20
149	Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage. Thrombosis and Haemostasis, 2008, 100, 642-7.	3.4	19
150	CTC Technologies and Tools. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2018, 93, 1197-1201.	1.5	18
151	Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC). Medical Oncology and Tumor Pharmacotherapy, 1999, 16, 177-187.	1.1	17
152	Interpolation method for accurate affinity ranking of arrayed ligand-analyte interactions. Analytical Biochemistry, 2016, 500, 21-23.	2.4	17
153	Trends in SPR Cytometry: Advances in Label-Free Detection of Cell Parameters. Biosensors, 2018, 8, 102.	4.7	17
154	Detection of extracellular vesicles in plasma and urine of prostate cancer patients by flow cytometry and surface plasmon resonance imaging. PLoS ONE, 2020, 15, e0233443.	2.5	17
155	A microwell array platform to print and measure biomolecules produced by single cells. Lab on A Chip, 2019, 19, 1850-1859.	6.0	16
156	Automatic lineage assignment of acute leukemias by flow cytometry. Cytometry, 1993, 14, 862-875.	1.8	15
157	Assessment of Hematopoietic Cell Differentiation by Multidimensional Flow Cytometry*. Stem Cells and Development, 1993, 2, 431-447.	1.0	15
158	CD4+ T lymphocytes enumeration by an easy-to-use single platform image cytometer for HIV monitoring in resource-constrained settings. Cytometry Part B - Clinical Cytometry, 2007, 72B, 397-407.	1.5	14
159	A microfluidic chip for high resolution Raman imaging of biological cells. RSC Advances, 2015, 5, 49350-49355.	3.6	14
160	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. European Urology Focus, 2018, 4, 235-244.	3.1	14
161	Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material. Breast Cancer Research and Treatment, 2019, 175, 451-458.	2.5	14
162	Cell analysis system based on compact disk technology. Cytometry, 2002, 47, 173-182.	1.8	13

#	ARTICLE	IF	CITATIONS
163	An Immunomagnetic Single-Platform Image Cytometer for Cell Enumeration Based on Antibody Specificity. <i>Vaccine Journal</i> , 2007, 14, 412-419.	3.1	13
164	All-printed cell counting chambers with on-chip sample preparation for point-of-care CD4 counting. <i>Biosensors and Bioelectronics</i> , 2018, 117, 659-668.	10.1	13
165	Circulating tumor cells (CTC) predict progression free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4010-4010.	1.6	13
166	Construction of repeat-free fluorescence in situ hybridization probes. <i>Nucleic Acids Research</i> , 2012, 40, e20-e20.	14.5	12
167	A novel side electrode configuration integrated in fused silica microsystems for synchronous optical and electrical spectroscopy. <i>Lab on A Chip</i> , 2014, 14, 1821.	6.0	12
168	Sample Preparation Methods Following CellSearch Approach Compatible of Single-Cell Whole-Genome Amplification: An Overview. <i>Methods in Molecular Biology</i> , 2015, 1347, 57-67.	0.9	12
169	Tumor cell capture from blood by flowing across antibody-coated surfaces. <i>Lab on A Chip</i> , 2019, 19, 1006-1012.	6.0	12
170	Optimal Halbach Configuration for Flow-through Immunomagnetic CTC Enrichment. <i>Diagnostics</i> , 2021, 11, 1020.	2.6	12
171	Detection of Aberrant Antigen Expression in Acute Myeloid Leukemia by Multiparameter Flow Cytometry. <i>Recent Results in Cancer Research</i> , 1993, 131, 185-196.	1.8	12
172	Re: Anti-“Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells. <i>Journal of the National Cancer Institute</i> , 2009, 101, 895-895.	6.3	11
173	Circulating Cancer Cells and Their Clinical Applications. <i>Clinical Chemistry</i> , 2011, 57, 1478-1484.	3.2	11
174	Flat-top illumination profile in an epifluorescence microscope by dual microlens arrays. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 324-331.	1.5	11
175	Raman and Fluorescence Spectral Imaging of Live Breast Cancer Cells Incubated with PEGylated Gold Nanorods. <i>Applied Spectroscopy</i> , 2012, 66, 66-74.	2.2	11
176	<i>CCR</i> 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4992-4995.	7.0	11
177	Leukocyte-Derived Extracellular Vesicles in Blood with and without EpCAM Enrichment. <i>Cells</i> , 2019, 8, 937.	4.1	11
178	The effects of splenic irradiation on lymphocyte subpopulations in chronic B-lymphocytic leukemia. <i>European Journal of Haematology</i> , 1988, 41, 496-505.	2.2	10
179	CD4 and CD8 enumeration for HIV monitoring in resource-constrained settings. <i>Cytometry Part B - Clinical Cytometry</i> , 2009, 76B, 118-126.	1.5	10
180	Quantitative detection of gold nanoparticles on individual, unstained cancer cells by scanning electron microscopy. <i>Journal of Microscopy</i> , 2011, 244, 187-193.	1.8	10

#	ARTICLE	IF	CITATIONS
181	Self-Seeding Microwells to Isolate and Assess the Viability of Single Circulating Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 477.	4.1	10
182	Endothelium-Derived Extracellular Vesicles Associate with Poor Prognosis in Metastatic Colorectal Cancer. <i>Cells</i> , 2020, 9, 2688.	4.1	10
183	Detection of apoptosis in cancer cell lines using Surface Plasmon Resonance imaging. <i>Sensing and Bio-Sensing Research</i> , 2016, 7, 48-54.	4.2	9
184	Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	9
185	Flow cytometric characterization of chronic lymphocyte leukaemias using orthogonal light scattering and quantitative immunofluorescence. <i>Blut</i> , 1988, 56, 201-208.	1.2	8
186	Abnormal distribution of CD8 subpopulation in B-chronic lymphocytic leukemia identified by flow cytometry. <i>Leukemia Research</i> , 1988, 12, 551-557.	0.8	8
187	Temperature-Switch Cytometryâ€”Releasing Antibody on Demand from Inkjet-Printed Gelatin for On-Chip Immunostaining. <i>ACS Applied Materials & Interfaces</i> , 2016, 8, 27539-27545.	8.0	8
188	Multiplex Label Free Characterization of Cancer Cell Lines Using Surface Plasmon Resonance Imaging. <i>Biosensors</i> , 2019, 9, 70.	4.7	8
189	Microsieves for the detection of circulating tumor cells in leukapheresis product in non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2020, 9, 1093-1100.	2.8	8
190	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1653-1665.	2.8	8
191	Application of orthogonal light scattering for routine screening of lymphocyte samples. <i>Cytometry</i> , 1988, 9, 220-225.	1.8	7
192	Clinical evaluation of a simple image cytometer for CD4 enumeration on HIVâ€infectected patients. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, 31-36.	1.5	7
193	Modeling single cell antibody excretion on a biosensor. <i>Analytical Biochemistry</i> , 2016, 504, 1-3.	2.4	7
194	Efficient and error-free fluorescent gene tagging in human organoids without double-strand DNA cleavage. <i>PLoS Biology</i> , 2022, 20, e3001527.	5.6	7
195	Immunomagnetic Separation Technologies. <i>Recent Results in Cancer Research</i> , 2012, 195, 43-58.	1.8	6
196	Parallel probing of drug uptake of single cancer cells on a microfluidic device. <i>Electrophoresis</i> , 2018, 39, 548-556.	2.4	6
197	SEMâ€”Raman image cytometry of cells. <i>Analyst, The</i> , 2018, 143, 4495-4502.	3.5	6
198	Rate zonal centrifugation can partially separate platelets from plateletâ€derived vesicles. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1053-1059.	2.3	6

#	ARTICLE	IF	CITATIONS
199	Metastasis and Circulating Tumor Cells. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2012, 23, 87-97.	0.7	6
200	Cytotoxic lymphocytes in B-cell chronic lymphocytic leukemia. <i>Blut</i> , 1990, 60, 81-87.	1.2	5
201	Quantitative Analysis of Circulating Tumor Cells as a Survival Predictor in Metastatic Castration-Resistant Prostate Cancer: Missing Parts in a Superb Study. <i>Clinical Cancer Research</i> , 2009, 15, 1504-1505.	7.0	5
202	Programmable droplet-based microfluidic serial dilutor. <i>Journal of Industrial and Engineering Chemistry</i> , 2020, 91, 231-239.	5.8	5
203	Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework. <i>Clinical Cancer Research</i> , 2020, 26, 4892-4900.	7.0	5
204	High throughput surface plasmon resonance imaging method for clinical detection of presence and strength of binding of IgM, IgG and IgA antibodies against SARS-CoV-2 during CoViD-19 infection. <i>MethodsX</i> , 2021, 8, 101432.	1.6	5
205	Combining Contrast Invariant L1 Data Fidelities with Nonlinear Spectral Image Decomposition. <i>Lecture Notes in Computer Science</i> , 2017, , 80-93.	1.3	5
206	Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and survival. <i>British Journal of Cancer</i> , 2022, 126, 409-418.	6.4	5
207	Flow cytometric determination of circulating immune complexes with the indirect granulocyte phagocytosis test. <i>Cytometry</i> , 1985, 6, 316-320.	1.8	4
208	Controlled antibody release from gelatin for on-chip sample preparation. <i>Analyst, The</i> , 2016, 141, 3068-3076.	3.5	4
209	Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy. <i>Pharmacogenomics Journal</i> , 2021, 21, 152-164.	2.0	4
210	Organosilicon uptake by biological membranes. <i>Communications Biology</i> , 2021, 4, 704.	4.4	4
211	Evidence on the cost of breast cancer drugs is required for rational decision making. <i>Ecancermedalscience</i> , 2018, 12, 825.	1.1	3
212	An inkjet-printed polysaccharide matrix for on-chip sample preparation in point-of-care cell counting chambers. <i>RSC Advances</i> , 2020, 10, 18062-18072.	3.6	3
213	Abstract 5600: Establishment and characterization of a unique circulating tumor cells-derived xenograft (CDX) in prostate cancer. <i>Cancer Research</i> , 2018, 78, 5600-5600.	0.9	3
214	Detection of circulating tumor cells in blood of pancreatic ductal adenocarcinoma patients. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2020, 3, 83-97.	2.1	3
215	A rapid two-step method for elimination of bcl-2/IgH positive non-Hodgkin's lymphoma cells from human blood or marrow stem cells, employing immunomagnetic purging with streptavidin-coated ferrofluids. <i>Cytotherapy</i> , 1999, 1, 287-293.	0.7	2
216	<title>CellTracks: Cell analysis system for rare cell detection</title>. , 2002, , .		2

#	ARTICLE	IF	CITATIONS
217	Feasibility of a simple microsieve-based immunoassay platform. Journal of Immunological Methods, 2016, 437, 21-27.	1.4	2
218	EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer. Annals of Oncology, 2019, 30, ii7.	1.2	2
219	Abstract 1826: IMI's CANCER-ID: Status of liquid biopsy standardization. , 2016, , .		2
220	Measurement of the Drug Sensitivity of Single Prostate Cancer Cells. Cancers, 2021, 13, 6083.	3.7	2
221	Raman spectroscopy for the assessment of acute myeloid leukemia: a proof of concept study. Proceedings of SPIE, 2014, , .	0.8	1
222	Estimating The Drug Treatment Cost of Breast Cancer. Value in Health, 2017, 20, A430-A431.	0.3	1
223	Abstract 1459: Detection of EpCAM negative circulating tumor cells in CellSearch waste.. , 2013, , .		1
224	Abstract 513: Standardization of technologies for CTC, ctDNA and miRNA enrichment, isolation and analysis for liquid biopsies during the first year of IMI's CANCER-ID. , 2016, , .		1
225	Circulating tumor cells as a possible prognostic tool in newly diagnosed nonmetastatic colorectal cancer?. Journal of Clinical Oncology, 2012, 30, 395-395.	1.6	1
226	Abstract 4825: Circulating tumor cells in metastatic lung cancer enriched by EpCAM expression and physical characteristics. Cancer Research, 2014, 74, 4825-4825.	0.9	1
227	Abstract 1606: Single cell isolation and DNA analysis from circulating tumor cells using self-sorting nanowell plates. , 2015, , .		1
228	Abstract 377: EpCAM+ and EpCAM- circulating tumor cells in metastatic lung cancer. , 2015, , .		1
229	Abstract 1532: The isolation of CTC from diagnostic leukapheresis. , 2016, , .		1
230	Consensus statement on circulating biomarkers for advanced prostate cancer.. Journal of Clinical Oncology, 2018, 36, 299-299.	1.6	1
231	Broadband Raman Response Of Gold Nanorods With And Without Cancer Cells. , 2010, , .		0
232	203 INVITED Enumeration and Characterization of Circulating Tumour Cells. European Journal of Cancer, 2011, 47, S47.	2.8	0
233	Gold nanoparticles for tumour detection and treatment. , 2011, , .		0
234	The Expected Health Economic Value of Using Circulating Tumor Cells to Personalize Cancer Treatment. Value in Health, 2013, 16, A424.	0.3	0

#	ARTICLE	IF	CITATIONS
235	Distinguishing septic from normal donors by detection of sPLA2-IIA from human plasma using a microsieve-based immunoassay. Journal of Immunological Methods, 2017, 447, 86-91.	1.4	0
236	The cost of expensive breast cancer drugs. Annals of Oncology, 2017, 28, v398-v399.	1.2	0
237	Abstract 1730: Automatic classification of EpCAM+, Cytokeratin+ objects versus survival in castration resistant prostate cancer. , 2010, , .		0
238	Abstract 4175: Automated classification of circulating tumor cells optimized using clinical outcome of castration resistant prostate cancer patients. , 2011, , .		0
239	P4-07-01: Circulating Tumor Cells, Disease Recurrence and Survival in Newly Diagnosed Breast Cancer.. , 2011, , .		0
240	P4-07-09: Automated Quantitative Assessment of HER2 Expression of Circulating Tumor Cells (CTC) in Metastatic Breast Cancer (IC 2006â€œ04 Study).. , 2011, , .		0
241	P4-07-14: Circulating Tumor Cells (CTCs) Detection and HER2 Profiling by CellSearchÂ® in Non-Metastatic Breast Cancer: An International Ring Study To Assess Inter-Reader Variability.. , 2011, , .		0
242	Abstract 2396: Key factors for filtration of tumor cells from whole blood. , 2012, , .		0
243	Abstract 2391: All patients with metastatic breast, colorectal and prostate carcinoma have circulating tumor cells. , 2012, , .		0
244	Abstract 2368: Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non metastatic breast cancer. , 2012, , .		0
245	Prospective Study on the Clinical Relevance of Residual Disease in Patients with Acute Myeloid Leukemia in Complete Remission. Hamatologie Und Bluttransfusion, 1994, , 553-558.	0.0	0
246	Distribution of Cells with a â€œStem Cell Likeâ€œ Immunophenotype in Acute Leukemia. Hamatologie Und Bluttransfusion, 1996, , 506-513.	0.0	0
247	Abstract 3065: Single cell isolation and DNA analysis from circulating tumor cells using a self sorting nanowell plate. , 2014, , .		0
248	Abstract 3064: Importance of circulating tumor cells in newly diagnosed colorectal cancer. , 2014, , .		0
249	Abstract 389: The identity of all nucleated cells enriched by CellSearch. , 2015, , .		0
250	Abstract 367: Microfluidic devices for the interrogation of single circulating tumor cells. , 2015, , .		0
251	Abstract 387: Non small cell lung cancer and circulating tumor cell: A different expression of EpCam and cytokeratins. , 2015, , .		0
252	Abstract 1604: IMI CANCER-ID: Validation of novel blood-based biomarker technologies in clinical settings. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
253	Interrogating metastatic prostate cancer treatment switch decisions.. Journal of Clinical Oncology, 2016, 34, 296-296.	1.6	0
254	Circulating tumor cell (CTC) rise and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) with low baseline CTC counts.. Journal of Clinical Oncology, 2016, 34, 5042-5042.	1.6	0
255	Abstract LB-250: Liquid biopsy in NSCLC: EpCAM+ and EpCAM- circulating tumor cells, tumor derived extracellular vesicles and cell-free circulating tumor DNA. , 2017, , .		0
256	Abstract 1733: Automated identification of circulating tumor cells by image analysis. , 2017, , .		0
257	Abstract 3787: EpCAM- and EpCAM+ circulating tumor cells in metastatic prostate and breast cancer patients: a multicenter study. , 2017, , .		0
258	Abstract A051: Liquid biopsy by apheresis: Molecular characterization of circulating tumor cells and their organoid culture reflects inpatient heterogeneity and clonal evolution. , 2018, , .		0